Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642976 | 0.86 | HTR3A (0.54) | HTR3AL3MBTL1KDM4EMAPTHRH2 | |
| SCHEMBL11047774 | 0.75 | HTR3A (0.46) | HTR3AL3MBTL1HRH2HRH1HRH4 | |
| SCHEMBL9519546 | 0.72 | GABRR1 (0.41) | HTR3AL3MBTL1HRH2HRH1HRH4 | |
| SCHEMBL642623 | 0.71 | ALDH1A1 (0.47) | HTR3AALDH1A1HRH2HRH1HRH4 | |
| SCHEMBL9864182 | 0.71 | PSMD14 (0.44) | ALDH1A1L3MBTL1DAOKDM4EMAPT | |
| SCHEMBL11047575 | 0.71 | TAAR1 (0.51) | HTR3AL3MBTL1HRH2HRH1HRH4 | |
| SCHEMBL30003476 | 0.70 | TSHR (0.55) | ALDH1A1L3MBTL1DAOKDM4EMAPT | |
| SCHEMBL643810 | 0.70 | KDM4E (0.54) | ALDH1A1L3MBTL1HTR5ADAOKDM4E | |
| SCHEMBL216373 | 0.70 | KDM4E (0.54) | ALDH1A1L3MBTL1HTR5ADAOKDM4E | |
| SCHEMBL1154872 | 0.70 | TSHR (0.55) | ALDH1A1L3MBTL1DAOKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | claimed |
| EP-2296655-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | claimed |
| WO-2009140138-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | claimed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119807-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2296655-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009140138-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009140138-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088937-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076020-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | HTR3A 2291/4885ALDH1A1 899/4885L3MBTL1 4518/4885 |
| US-20090286829-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ADRA2C, ADRA2B, ADRB3 | HTR3A 28/4885ALDH1A1 1423/4885L3MBTL1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.